Výsledky neoadjuvantní CHT u ca ovaria

	Věk	St.	Eval.	Ascit	Histol.typ	G	Vs. CA 125	Vs. CEA	Cykly CHT	↓CA 125 2. C
1.	73	4	2	1	maligní bky		2055	3.36	5 (6)	
2.	61	4	1	1	serózní papil	3	10899.8	0.6	8	
3.	66	3	1	2	cystadenopa	2	107.6	0.4	6	20.5
4.	76	3	1	2	cystadenopa	2	236.7	0.9	3	101.5
5.	70	3	1	1	nízce diff mu	3	1250.3	0.2	7 (8)	
6.	69	2	1	2	cystadenoca	3	82	0.3	4	30.6
7.	60	3	1	1	nízce diff ser	3	1563.8	1.3	8 (10)	
8.	60	4	1	1	serozní papil	1	1309.1	0.5	8 (14)	
9.	57	3	1	1	cystadenoka	2	7164.2	5.3	4 (10)	88.3
10.	53	3	1	2	serózní střeo	2	241		5 (8)	16.5
11.	52	1	1	2	serózní cystadeno		26.9		3 (8)	
12.	50	3	2	1	serozní papil	3	4264	0.4	3 (8)	
13.	48	2	1	2	tubulopapilá	2	65.2	0.8	7	
14.	46	1	1	2	cystický seró	1	10.1	1.5	4 (6)	
15.	82	4	1	1	serózní papil	3	1115		8	219.7
18.	74	4	1	1	adenoCa mucinos		113.4	0.5	6	19.2
19.	72	3	1	1	mucinosni adenoc		3926		7	
21.	70	3	1	1	adenoca		5502.4	0.5	3 (6)	4486.3
22.	70	3	1	1	serósni cysta	3	482.5	0.5	4 (9)	61.4
24.	66	4	1		mucinosní cy	2	107.6	0.4	6	
25.	47	3	1	1	serózní papilární c		2364.1	0.5	4 (7)	240.8
27.	65	3	1	2	endometroic	2	286.8	0.7	3 (6)	16.4
28.	65	4	1	1	cystadenopa	2	495.8		4	926.2
29.	64	3	1	1	serozní papil	3	105.8	0.5	3 (6)	86.2
30.	64	3	1	2	papilár.se	3	1752	1.7	4 (7)	787
31.	62	1	1		mucinózní ca	1	17.5	0.5	3 (6)	
32.	58	3	1	2	nízce diferno	3	10275.2	0.1	4 (8)	4457.3
33.	57	4	1		adenoca					
34.	57	3	1	1	serozni papil	3	332		6	
35.	55	3	1	1	adenoca	3	1987	1	6	448
36.	54	4	2	1	maligní bky	3	637		3 (8)	
37.	52	3	1	2	nizce differe	3	1944.2	1.8	3 (8)	
38.	50	4	2	1	serózní papil	3			4 (7)	49.4
39.	40	1	1		dysgerminom		11.8		3	
40.	31	3	1	2	malob. typ c	3	13.8	0.2	4 (6)	6.9
41.	79	3	1				2704.2	2.9	1	
42.	47	3	1	1	serózní papil	3	376	1.5	6 (9)	
43.	49	3	1	2	serózní aden	3	6556.3	0.5	6 (8)	1062.7
44.	73	3	1	1	serózní papil	3	1070	0.6	3 (6)	
45.	73	3	1		endometroic	3	455.5	6.3	4 (8)	
46.	73	1	1		mucinozni ca borc		8.5	2.1	3	
47.	62	3	1	1	serózní papil	3	1186.1	2.2	4 (8)	
48.	70	4	1	1	serózní papil	3				
49.	70	3	1	2	papilární	3	281	2.2	4 (7)	5.3
50.	70	3	1	1	serózní papil	2	160	0.6	3 (7)	146.1
51.	68	4	1	1	karcinom me	4			4 (5)	
52.	66	4	1	1	cystadenoka	3	11881		3	1438.8

53.	55	4	1	2	endometroic	3	254.4		7	23.6
54.	66	3	1	1	nediferencov	3	3599.4		6 (9)	1635
55.	65	3	1	1	papilární	3	1785	4.2	6 (13)	60.5
56.	64	4	1	1	serózní papil	3	221.1	0.5	4	152.9
57.	39	3	1	1	serózní papil	3	135	1.3	7	
58.	65	3	1	1		3	1304.5	1.9	4 (7)	35
59.	64	3	1	2	serózní papil	3	197.7	2.9	4 (5)	163.3
60.	62	1		2	endometroic	2	54.4	1.6	5	
61.	62	4	1	1	serózní papil	3	13625	0.8	3 (6)	136.6
62.	63	3	1	1	serozní papil	3	6627.9		1	
63.	62	3	1		serozní palilá	3	270.4		3 (6)	17.5
64.	61	4	1	1		4	378.7	1,1po 1C	1	
65.	55	1		2	endometroic	2	5.8	1.5	4	
66.	60	3	1	1	papilární	3	1249	4.1	3 (6)	24.3
67.	58	1	2	2	clear cell ca	2	27.4	1.5	2 (6)	13.7
68.	41	3	1	1	serózní papil	1	1808	4.6	6	
69.	55	3	1	1	serózní papil	1	174.2	0.8	7	110.1
70.	56	3	1	2	erozní cystac	3	8	0.5	3 (6)	6.5
71.	55	3	1	1	maligní bky	3	1307	3.4	3 (6)	
72.	55	3	1	1	mucinózní ac	3	6042	5986	3 (6)	
74.	51	3	1	1	nedif.ca	3	1.4	649.8	3 (10)	1751
75.	51	3	1	2	serózní aden	3	105.9		3	
76.	49	3	1	1	serozní papil	3	2947.5	0.9	4 (6)	
77.	47	4	1	1	serózní papilární		1781.8	1.8	3 (8)pal.	206.7
78.	80	3	1	1	serózní ca	3	660	0.5	1	
79.	76	3	1	1	serózní papil	3	2878.9	0.8	4 (7)	151.6
80.	75	3	1	1	serózní papil	3	7935.3	0.5	3pal.	3249.8
81.	75		1	1	serózní papil	3	4517.4	3	2	
82.	74	3	1	2	malubuň.	3	392	1.3	4(7)	3.1
83.	75	3	1	1	serózní papil	4	15517	0.7	3(7)	1935.5
84.	74	3	1	1	adenoca		174	4.6	3 (3)	
85.	73	3	1	1	nízce dif	3	2.8	531.3	4 (7)	61.9
86.	71	3	1	1	serózní papil	3	8640	1.9	7	3080.4
87.	71	3	1	2		3	942.9	0.5	7	134.3
88.	70	3	1	1	papil.ser	2	116	1.2	4 (7)	3.8
89.	69	3	1	1	serózní papil	2	3551.1	0.5	7	968.3
90.	67	3	1	1	nediferencov	3	1029.9	0.5	3 (8)	141.2
91.	66	3	1	1	serózní papil	2	465.8	0.5	4 (7)	165.4
92.	45	3	1	2	serózní papil	3	65	0.5	4 (7)	11.3
93.	64	3	1	2	serózní papil	3	419.1	0.5	4 (7)	33.9
94.	64	3	1	1	papilární	2	125		4 (7)	
95.	64		1	1	adeno ca		544.2		8	117.6
96.	63	3	1	1	serózní papil	3	415	0.5	7	365.9
97.	61	3	1	1	serózní papil	3	1444.4	0.5	6 (8)	229.1
98.	62		1	1	serózní papil	2	124.3	0.5	7	20.7
99.	60	3	1	1	serózní papil	2		0.5	5	301.5
100.	59	2	1	2	serózní papil	1	61.5		4 (7)	
101.	59	3	1	2	nízce dif	3	2.7	29.5	3 (6)	
102.	58		1	1	serózní papil	3	1486.4	1.2	7	2020.1
103.	58	1	1	2	endometroic	1	12.7	0.9	3 (6)	

104	56	3	1	1	serózní papil	2	593.1	1.7	3 (6)	150.6
105.	56	3	1	1	serózní papil	2	436.4	0.5	3 (7)	212.6
106.	55	4	1	2	serozní cysta	2	3088	1.2	8 pal.	180
107.	55	3	1	1		3	1088.2	10.9	6	
109.	52	3	1	2	papil.ser	3	201	3.2	4 (8)	273
110.	51	3	1	2	serózní papil	3	511.3	1.5	6 (9)	6.5
111.	51	3	1	1	cystadenoca	2	91.2	60	4	35.9
112.	49	1	1	2	endometroic	3	14.7	0.5	3 (6)	8.7
113.	47		1	2	epiteliální ad	3	121.1	0.5	3 (4)	
114.	46	3	2	2	serózní papil	3	86.7	1.7	4 (7)	11
115.	46	1	1	2	serozní neivazivní		12.2	2.7	3	
116.	44	3	1	2	serózní papil	3	1586.7	0.5	4 (7)	
118.	81	3	1	2	serózní aden	2	1437	1.1	4	
119.	79	3	1	1	serózní papil	3	67.3	0.6	7	
120.	51	2	1	2	serózní papil	3	17.3	0.6	3 (6)	5.4
121.	76	3	1	2	serózní papil	2	209.8	0.9	3 (6)	12.3
122.	76	3	1	1	serózní papil	3	454.1	1	6 pal.	
123.	76	3	1	1	serózní papil	3	2156	0.6	5	
124.	65	4	1	1	Sertoli-Leydi	3			4	130.7
125.	74	3	1	1	papilární	3	146	1.9	6	
127.	68		1	1	serózní papil	3	538.9	0.8	7	
128.	67	3	2	2		3	192	13.9	3 (8)	
129.	66	3	1	1	serózní papil	3	500		6	
130.	61	3	1	1	serózní papilární a		157.6	0.5	3 (6)	10.2
131.	61	3	1	1	sereozni pap	1	179.4	7.9	4 (8)	35
132.	60		1	1	serózní papil	3	469	0.9		43.9
133.	50	1	1	2	granullosa cell tu		33.6	3.4	4	
134.	59		1	1	invazivní ca	2	317.8	1.7	3 (5)	41.8
135.	58	3	2	1	serózní papil	3	4547.5	4.7	3 (7)	334.8
136.	58	3	1	1	serózní papil	3	2844	1.8	4 (9	
137.	56	3	1	1	serózní papil	2	436.4	0.5	3 (7)	212.6
138.	56	1	1	1	serózní aden	2	64		3 (6)	

↓CA 125 3.C	↓CA 125 4. C	2. eval.	Dat. Op.	Opt. Db.	Adj. CHT	TTP	Dat.zah II.linie	PK.
	96.4	1	inop					
6507	3492.5	1	inop			7	1/11/2007	
15			3/16/2007	2		18		
94.5			#########	1	1/4/2007			
44			#########	1	19/1/2007	23 (32)	6/5/2009	2
	14.7	1	4/21/2006	1		47	3/23/2011	2
9.5		1	8/15/2006	1	9/6/2006			1
1283.9						17		
22.1			6/5/2006	1	6/20/2006	41	8/19/2011	2
			#########	1	1/8/2007	51	1/10/2011	2
11.4			10/6/2006	1	Oct-06			1
46.7			#########	1				1
	24.5		9/25/2006	1		16 (24)		2
8.3			1/27/2010	1	2/18/2010			1
244.2	244.3		inop			5		2
			5/10/2007	1				
		1	inop					2
152.4			8/30/2007	1	9/26/2007	13	8/21/2008	2
18.9			6/19/2007	1	7/19/2007	16		
20.5	15		3/16/2007	2	30.4.2007pal	15	4/30/2007	2
			#########	1	11/18/2010			1
			2/25/2008	1	3/19/2008	20	2/4/2010	2
84.3	9.8		6/4/2007	1	6/22/2007	11	5/15/2008	2
17.9	16.5		inop	2	3/20/2008	26	12/14/2009	2
			5/21/2007	1				1
1446.2			3/13/2007	2	4/11/2007	9		
	7.4		#########	1		5	2/20/2008	2
77.8			#########	1		4	4/1/2008	2
11.1		1	7/3/2007	1		13	5/12/2008	
198.3			1/16/2007	2	2/6/2007	11 (14)	2/20/2008	2
16.4			9/18/2007	1	10/10/2007	14	12/11/2008	2
			9/25/2007	1				1
			#########	2	1/17/2007		3/7/2007	2
130.5	50.8	1	5/27/2010	1	7/2/2010			1
190.7	74.5		11/2/2010	2	12/2/2010	5	3/23/2011	2
10.1		1	6/12/2008	1	7/4/2008	5	1/8/2009	2
16.7			9/10/2008	1	10/8/2008			1
			9/7/2008	1				1
77.9			6/26/2008	1	7/21/2008	20	5/26/2010	2
4.4	3.1	1	9/3/2008	1	9/29/2008			1
98.6		1	inop			17		2
124.4		1	inop					2
530.7			4/19/2008	1	5/28/2008	14	6/10/2009	2

	10.4		2/15/2011	1	23.3.2011RT			1
249	34.4	1	10/7/2008	2	20.11.200812		16.11.20102	
32.4	20.1	1	5/22/2008	2	6/24/2008	8	4/22/2009	2
122.6		1	inop				2/4/2008	2
56		2	2/22/2011	1				1
			2/4/2009	1	2/24/2009	10		2
34.8			7/14/2008	1				
24			12/9/2008	1				1
21.4			2/12/2009	1	2/26/2009	9	10/9/2009	2
			4/21/2008	2				
14.1			4/16/2009	1	5/5/2009			1
								2
4.9			Apr-02	1	20.7.2006pal.	48	2/11/2009	2
22.1	18	1	6/25/2008	1	11/7/2008	7	2/23/2009	1
12.5	30.1	1	5/27/2008	1	4/21/2008	25	žádná	2
88.2		2	4/27/2010	1				1
	12.2	1	5/19/2008	1	9/23/2008	3	2/24/2009	2
			#########	1	1/12/2009			1
115			4/11/2008	1	5/12/2008			1
1853						5	4/30/2009	2
750	181	1	2/5/2009	1	10/14/2008			1
105			inop					
53.7	4.8		3/26/2009	1	12/3/2008			1
138.7			7/31/2008	2	8/20/2008	15	10/2/2009	2
34.2			1/5/2010	1	2/1/2010	10		12
1917.1							symptom.	2
2.1	2.2	2	inop			14	5/14/2009	2
911.6		1	inop				11/1/2010	2
								2
	58.3	1	9/10/2009	2	6/10/2009	15	2/11/2011	2
2440.9			8/19/2009	1		8	3/15/2010	2
28.3		1	inop			9	1/19/2010	2
2.5	2.8	1	2/24/2009	2	3/20/2009	8	1/11/2010	2
308.6		1	inop			9	7/27/2010	2
25.2			11/2/2009	1	11/19/2009	11		2
34.6			1/19/2010	1	2/22/2010			
10.2			11/3/2010	1	11/19/2010			1
			6/9/2009	1	7/15/2009			1
			7/21/2009	1	8/24/2009			1
129.5			inop					2
335		1	inop				5/24/2010	2
103.9			8/10/2009	1	9/21/2009	15	9/15/2010	2
27.7		1	6/9/2010	1		11	3/14/2011	
89.5	39.6		inop				7/10/2009	2
	13		#########	1	11/30/2009			1
	33.1	1	7/28/2009	2	26,4,2009			1
	17.2	1	inop			6	11/25/2009	2
3.6			3/18/2009	1	4/9/2009			1

			6/18/2009	1	7/15/2009	7	1/25/2010	2
113.3			2/3/2010	1	2/24/2010			1
						6	11/26/2009	2
189	269.2	1	inop			8	12/16/2009	2
260	235	1	#########	2	11/19/2009	3	7/12/2010	2
	11.9	1	5/21/2010	1	3/20/2009			1
26.5			6/1/2009	1	7/3/2009			1
8.5			12/3/2009	1	12/16/2009			1
13.1			1/27/2009	1	2/13/2009			1
			#########	1				1
23.6			1/11/2010	1	1/28/2010			1
	1528.4		inop			1		2
85	44.3	1	inop				9/16/2010	2
5.5			3/19/2010	1	4/13/2010			1
			2/25/2010	1	3/16/2010			1
8.6		1	inop					2
	58.7							
95.6								
22			5/4/2011	1				1
28.7	9.7	1	5/18/2010	1		12		2
8.1		1	#########	2	7/14/2010			2
372		1						1
			5/19/2010	1	7/1/2010			1
12.1	11.5		1/24/2011	1	11/19/2010			1
			6/16/2010	1	7/14/2010			1
			7/30/2010	1				1
			Aug-10	1	9/16/2010			1
213.5	86.2	1	#########	1	7/20/2010			1
256			8/31/2010	1	10/11/2010			1
	16.8		2/3/2010	1	2/24/2010			1
14.8			11/8/2010	1	2/15/2010			1

Přežití	Doba	Cykly CHT b	Cykly CHT celk	Vs. CA 125	↓CA 125 2. C	↓CA 125 3.C	↓CA 125 4. C
2	18	5	6	2055	NaN	NaN	96.4
2	13	8	8	10899.8	NaN	6507	3492.5
2	29	6	6	107.6	20.5	15	NaN
2	13	3	3	236.7	101.5	94.5	NaN
2	54	7	8	1250.3	NaN	44	NaN
1		4	4	82	30.6	NaN	14.7
1		8	10	1563.8	NaN	9.5	NaN
2	21	8	14	1309.1	NaN	1283.9	NaN
1		4	10	7164.2	88.3	22.1	NaN
1		5	8	241	16.5	NaN	NaN
1		3	8	26.9	NaN	11.4	NaN
1		3	8	4264	NaN	46.7	NaN
2	27	7	7	65.2	NaN	NaN	24.5
1		4	6	10.1	NaN	8.3	NaN
2	9	8	8	1115	219.7	244.2	244.3
2	10	6	6	113.4	19.2	NaN	NaN
2	11	7	7	3926	NaN	NaN	NaN
2	25	3	6	5502.4	4486.3	152.4	NaN
2	23	4	9	482.5	61.4	18.9	NaN
2	29	6	6	107.6	NaN	20.5	15
1		4	7	2364.1	240.8	NaN	NaN
2	40	3	6	286.8	16.4	NaN	NaN
2	6	4	4	495.8	926.2	NaN	NaN
2	36	3	6	105.8	86.2	84.3	9.8
2	32	4	7	1752	787	17.9	16.5
1		3	6	17.5	NaN	NaN	NaN
2	15	4	8	10275.2	4457.3	1446.2	NaN
2		NaN	NaN	NaN	NaN	NaN	NaN
2	17	6	6	332	NaN	NaN	7.4
2	23	6	6	1987	448	77.8	NaN
2	32	3	8	637	NaN	11.1	NaN
2	37	3	8	1944.2	NaN	198.3	NaN
2	27	4	7	NaN	49.4	16.4	NaN
1		3	3	11.8	NaN	NaN	NaN
2	9	4	6	13.8	6.9	NaN	NaN
2	4	1	1	2704.2	NaN	NaN	NaN
1		6	9	376	NaN	130.5	50.8
1		6	8	6556.3	1062.7	190.7	74.5
2	17	3	6	1070	NaN	10.1	NaN
1		4	8	455.5	NaN	16.7	NaN
1		3	3	8.5	NaN	NaN	NaN
1		4	8	1186.1	NaN	77.9	NaN
2	11	NaN	NaN	NaN	NaN	NaN	NaN
1		4	7	281	5.3	4.4	3.1
1		3	7	160	146.1	98.6	NaN
2	12	4	5	NaN	NaN	124.4	NaN
2	23	3	3	11881	1438.8	530.7	NaN

1		7	7	254.4	23.6	NaN	10.4
2	31	6	9	3599.4	1635	249	34.4
2	44	6	13	1785	60.5	32.4	20.1
2	24	4	4	221.1	152.9	122.6	NaN
1		7	7	135	NaN	56	NaN
		4	7	1304.5	35	NaN	NaN
2	5	4	5	197.7	163.3	34.8	NaN
1		5	5	54.4	NaN	24	NaN
2	26	3	6	13625	136.6	21.4	NaN
2	1	1	1	6627.9	NaN	NaN	NaN
1		3	6	270.4	17.5	14.1	NaN
2	1	1	1	378.7	NaN	NaN	NaN
1		4	4	5.8	NaN	4.9	NaN
2	11	3	6	1249	24.3	22.1	18
1		2	6	27.4	13.7	12.5	30.1
1		6	6	1808	NaN	88.2	NaN
2	14	7	7	174.2	110.1	NaN	12.2
1		3	6	8	6.5	NaN	NaN
1		3	6	1307	NaN	115	NaN
2	22	3	6	6042	NaN	1853	NaN
1		3	10	1.4	1751	750	181
2	5	3	3	105.9	NaN	105	NaN
1		4	6	2947.5	NaN	53.7	4.8
2	35	3	8	1781.8	206.7	138.7	NaN
2	3	1	1	660	NaN	NaN	NaN
2	16	4	7	2878.9	151.6	34.2	NaN
2	7	3	3	7935.3	3249.8	1917.1	NaN
2	3	2	2	4517.4	NaN	NaN	NaN
2	15	4	7	392	3.1	2.1	2.2
2	19	3	7	15517	1935.5	911.6	NaN
2	5	3	3	174	NaN	NaN	NaN
1		4	7	2.8	61.9	NaN	58.3
1		7	7	8640	3080.4	2440.9	NaN
2	18	7	7	942.9	134.3	28.3	NaN
2	28	4	7	116	3.8	2.5	2.8
2	19	7	7	3551.1	968.3	308.6	NaN
1		3	8	1029.9	141.2	25.2	NaN
1		4	7	465.8	165.4	34.6	NaN
1		4	7	65	11.3	10.2	NaN
1		4	7	419.1	33.9	NaN	NaN
1		4	7	125	NaN	NaN	NaN
2	12	8	8	544.2	117.6	129.5	NaN
1		7	7	415	365.9	335	NaN
1		6	8	1444.4	229.1	103.9	NaN
1		7	7	124.3	20.7	27.7	NaN
2	24	5	5	NaN	301.5	89.5	39.6
1		4	7	61.5	NaN	NaN	13
2		3	6	2.7	NaN	NaN	33.1
2	20	7	7	1486.4	2020.1	NaN	17.2
1		3	6	12.7	NaN	3.6	NaN

1		3	6	593.1	150.6	NaN	NaN
1		3	7	436.4	212.6	113.3	NaN
2	22	8	8	3088	180	NaN	NaN
2	15	6	6	1088.2	NaN	189	269.2
2	14	4	8	201	273	260	235
1		6	9	511.3	6.5	NaN	11.9
2	5	4	4	91.2	35.9	NaN	NaN
1		3	6	14.7	8.7	26.5	NaN
1		3	4	121.1	NaN	8.5	NaN
1		4	7	86.7	11	13.1	NaN
1		3	3	12.2	NaN	NaN	NaN
1		4	7	1586.7	NaN	23.6	NaN
1		4	4	1437	NaN	NaN	1528.4
1		7	7	67.3	NaN	85	44.3
1		3	6	17.3	5.4	5.5	NaN
1		3	6	209.8	12.3	NaN	NaN
1		6	6	454.1	NaN	8.6	NaN
1		5	5	2156	NaN	NaN	58.7
2	5	4	4	NaN	130.7	95.6	NaN
1		6	6	146	NaN	22	NaN
1		7	7	538.9	NaN	28.7	9.7
1		3	8	192	NaN	8.1	NaN
1		6	6	500	NaN	372	NaN
1		3	6	157.6	10.2	NaN	NaN
1		4	8	179.4	35	12.1	11.5
1		NaN	NaN	469	43.9	NaN	NaN
1		4	4	33.6	NaN	NaN	NaN
1		3	5	317.8	41.8	NaN	NaN
1		3	7	4547.5	334.8	213.5	86.2
1		4	9	2844	NaN	256	NaN
1		3	7	436.4	212.6	NaN	16.8
1		3	6	64	NaN	14.8	NaN

Přežití	Doba	1.Operace	2.Operace	TTP	Opt. Db.	St.	G
2	18	0	0	NaN	NaN	4	NaN
2	13	0	1	7	NaN	4	3
2	29	1	0	18	2	3	2
2	13	1	0	NaN	1	3	2
2	54	1	1	23	1	3	3
1	NaN	1	1	47	1	2	3
1	NaN	1	0	NaN	1	3	3
2	21	0	0	17	NaN	4	1
1	NaN	1	1	41	1	3	2
1	NaN	1	1	51	1	3	2
1	NaN	1	0	NaN	1	1	NaN
1	NaN	1	0	NaN	1	3	3
2	27	1	0	16	1	2	2
1	NaN	1	0	NaN	1	1	1
2	9	0	0	5	NaN	4	3
2	10	1	0	NaN	1	4	NaN
2	11	0	0	NaN	NaN	3	NaN
2	25	1	1	13	1	3	NaN
2	23	1	0	16	1	3	3
2	29	1	1	15	2	4	2
1	NaN	1	0	NaN	1	3	NaN
2	40	1	1	20	1	3	2
2	6	0	0	NaN	NaN	4	2
2	36	1	1	11	1	3	3
2	32	0	1	26	2	3	3
1	NaN	1	0	NaN	1	1	1
2	15	1	0	9	2	3	3
2	NaN	0	0	NaN	NaN	4	NaN
2	17	1	1	5	1	3	3
2	23	1	1	4	1	3	3
2	32	1	1	13	1	4	3
2	37	1	1	11	2	3	3
2	27	1	1	14	1	4	3
1	NaN	1	0	NaN	1	1	NaN
2	9	1	1	NaN	2	3	3
2	4	0	0	NaN	NaN	3	NaN
1	NaN	1	0	NaN	1	3	3
1	NaN	1	1	5	2	3	3
2	17	1	1	5	1	3	3
1	NaN	1	0	NaN	1	3	3
1	NaN	1	0	NaN	1	1	NaN
1	NaN	1	1	20	1	3	3
2	11	0	0	NaN	NaN	4	3
1	NaN	1	0	NaN	1	3	3
1	NaN	0	0	17	NaN	3	2
2	12	0	0	NaN	NaN	4	4
2	23	1	1	14	1	4	3

1	NaN	1	0	NaN	1	4	3
2	31	1	1	NaN	2	3	3
2	44	1	1	8	2	3	3
2	24	0	1	NaN	NaN	4	3
1	NaN	1	0	NaN	1	3	3
NaN	NaN	1	0	10	1	3	3
2	5	1	0	NaN	1	3	3
1	NaN	1	0	NaN	1	1	2
2	26	1	1	9	1	4	3
2	1	1	0	NaN	2	3	3
1	NaN	1	0	NaN	1	3	3
2	1	0	0	NaN	NaN	4	4
1	NaN	1	1	48	1	1	2
2	11	1	1	7	1	3	3
1	NaN	1	1	25	1	1	2
1	NaN	1	0	NaN	1	3	1
2	14	1	1	3	1	3	1
1	NaN	1	0	NaN	1	3	3
1	NaN	1	0	NaN	1	3	3
2	22	0	1	5	NaN	3	3
1	NaN	1	0	NaN	1	3	3
2	5	0	0	NaN	NaN	3	3
1	NaN	1	0	NaN	1	3	3
2	35	1	1	15	2	4	NaN
2	3	0	0	NaN	NaN	3	3
2	16	1	0	10	1	3	3
2	7	0	1	NaN	NaN	3	3
2	3	0	0	NaN	NaN	NaN	3
2	15	0	1	14	NaN	3	3
2	19	0	1	NaN	NaN	3	4
2	5	0	0	NaN	NaN	3	NaN
1	NaN	1	1	15	2	3	3
1	NaN	1	1	8	1	3	3
2	18	0	1	9	NaN	3	3
2	28	1	1	8	2	3	2
2	19	0	1	9	NaN	3	2
1	NaN	1	0	11	1	3	3
1	NaN	1	0	NaN	1	3	2
1	NaN	1	0	NaN	1	3	3
1	NaN	1	0	NaN	1	3	3
1	NaN	1	0	NaN	1	3	2
2	12	0	0	NaN	NaN	NaN	NaN
1	NaN	0	1	NaN	NaN	3	3
1	NaN	1	1	15	1	3	3
1	NaN	1	1	11	1	NaN	2
2	24	0	1	NaN	NaN	3	2
1	NaN	1	0	NaN	1	2	1
2	NaN	1	0	NaN	2	3	3
2	20	0	1	6	NaN	NaN	3
1	NaN	1	0	NaN	1	1	1

1	NaN	1	1	7	1	3	2
1	NaN	1	0	NaN	1	3	2
2	22	0	1	6	NaN	4	2
2	15	0	1	8	NaN	3	3
2	14	1	1	3	2	3	3
1	NaN	1	0	NaN	1	3	3
2	5	0	0	NaN	NaN	3	2
1	NaN	1	0	NaN	1	1	3
1	NaN	1	0	NaN	1	NaN	3
1	NaN	1	0	NaN	1	3	3
1	NaN	1	0	NaN	1	1	NaN
1	NaN	1	0	NaN	1	3	3
1	NaN	0	0	1	NaN	3	2
1	NaN	0	1	NaN	NaN	3	3
1	NaN	1	0	NaN	1	2	3
1	NaN	1	0	NaN	1	3	2
1	NaN	0	0	NaN	NaN	3	3
1	NaN	0	0	NaN	NaN	3	3
2	5	0	0	NaN	NaN	4	3
1	NaN	1	0	NaN	1	3	3
1	NaN	1	0	12	1	NaN	3
1	NaN	1	0	NaN	2	3	3
1	NaN	0	0	NaN	NaN	3	3
1	NaN	1	0	NaN	1	3	NaN
1	NaN	1	0	NaN	1	3	1
1	NaN	1	0	NaN	1	NaN	3
1	NaN	1	0	NaN	1	1	NaN
1	NaN	1	0	NaN	1	NaN	2
1	NaN	1	0	NaN	1	3	3
1	NaN	1	0	NaN	1	3	3
1	NaN	1	0	NaN	1	3	2
1	NaN	1	0	NaN	1	1	2

Věk- věk pacientky v době diagnózy
Stádium
Evaluace (LPSK před zahájením léčby) - 1=ano, 2=ne
Ascites- 1=ano, 2=ne
Histologický typ
Grading
Vstupní předléčebná hodnota CA 125 a CEA
Počet cyklů neoadj. CHT - v závorce pak uveden počet cyklů celkem (neoadj. + adj.)
Pokles CA 125 po 2. cyklu
Pokles CA 125 po 3. cyklu
Pokles CA 125 po 4. cyklu (v případě, že nejsou údaje z předchozích cyklů)
2. evaluace- 1=ano (obyvkle u inop. Pacientek)
Datum operace- pokud nebyla operována napsat inop
Optimální debulking (reziduum do 1cm)- 1=ano, 2=ne
Adjuvantní CHT- interval od operace do zahájení adjuvantní CHT
TTP- doba do relapsu (od poklesu markerů do jejich elevace- počet měsíců)
2.linie- datum zahájení
PK= poseldní kontrola- 1=bez známek onemocnění, 2= se známkami onemocnění
Přežití- 1=žije, 2=zemřela
Doba- počet měsíců od stanovení dg do smrti